Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

NACompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

August 15, 2024

Study Completion Date

February 13, 2025

Conditions
Cancer
Interventions
OTHER

Pre-Test Intervention

Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.

OTHER

Standard of Care

Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)

OTHER

Post-Test Intervention

Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.

Trial Locations (1)

19104

Abramson Cancer Center at University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Fox Chase Cancer Center

OTHER

collaborator

Basser Center for BRCA

UNKNOWN

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER